Psilocybin for depression and trauma: an honest look at the evidence

Every so often someone asks me what I think about psilocybin, the active compound in so-called magic mushrooms, for depression or trauma. I understand why. The personal stories can be striking, and the headlines have been breathless. I was curious myself about what the evidence actually shows, so I went and read it. What follows is an honest summary, written for people who want the real picture rather than the hype. But it comes wrapped in caveats that I need you to take as seriously as the evidence itself.

Please read this before anything else

• This is not medical advice, and it is not a recommendation. I am a counselling psychologist, not a medical doctor. I cannot advise on medication or treatment, I cannot speak to anyone's individual circumstances or presentation without assessing them, and even then I would never recommend this as a course of treatment.
• Psilocybin is illegal in the UK. It is a Class A, Schedule 1 drug. Possessing, growing or supplying it is a criminal offence. Nothing here is an encouragement to obtain or use it, and this is not a how-to.
• The promising results are from supervised clinical trials, not from people self-treating. The benefits seen in research depend on careful screening, a prepared setting, trained professionals present, and structured follow-up. None of that can be replicated alone at home, and trying to can be genuinely dangerous.
• If you are struggling, please speak to your GP or a mental-health professional about evidence-based options. There are real ones, and they are at the end of this piece.

First, a distinction that changes everything: microdosing is not the same thing

The single biggest source of confusion here is that two very different practices get talked about as if they were one. They are not, and the evidence for them points in almost opposite directions.

• Microdosing means taking a tiny, sub-perceptual dose, far too small to produce a noticeable "trip," typically every few days, in the hope of a gentle lift in mood, focus or creativity.
• Psychedelic-assisted therapy means a single (or small number of) full, clearly psychoactive doses, taken in a clinic, with psychological preparation beforehand, a trained therapist present throughout the several-hour experience, and integration sessions afterwards.

When you read about dramatic results for depression, those come from the second of these, not the first. So it is worth being clear-eyed: the practice most people can imagine doing quietly at home, microdosing, is the one with the weakest evidence, and the practice with the more promising evidence is the one that only exists, legally and safely, inside a research setting.

The evidence for supervised high-dose therapy in treatment-resistant depression

This is where the science is genuinely interesting. The largest trial to date, run by COMPASS Pathways and published in the New England Journal of Medicine in 2022, gave 233 people with treatment-resistant depression a single dose of psilocybin alongside psychological support.1 A 25mg dose produced a significantly greater reduction in depression scores at three weeks than a tiny 1mg comparison dose. That is a real and notable signal.

But the caveats inside the science matter. The effect, while real, was not a miracle: roughly a fifth of the 25mg group still had a durable response at twelve weeks, and adverse effects (including, in a small number, suicidal thoughts or self-harm) were reported.1 An earlier Imperial College London trial that compared psilocybin against a standard antidepressant, escitalopram, did not find psilocybin clearly superior on its main measure, though it looked favourable on several secondary ones, and the authors stressed it was too small to settle the question.2 In short: promising, not proven. Psilocybin therapy is still in clinical trials and is not an approved or available treatment in the UK or, for routine care, anywhere else.

The evidence for microdosing: much weaker than the enthusiasm suggests

Here the honest answer is uncomfortable for the hype. The glowing reports for microdosing come overwhelmingly from anecdotes and from open-label studies, where people know they are taking the substance and expect it to help. When researchers have run proper placebo-controlled studies, the picture largely collapses.

The most elegant of these was a large self-blinding citizen-science study in which participants could not tell whether they were taking a microdose or a placebo.3 People's mental-health scores improved, but they improved just as much in the placebo group, and what best predicted improvement was not what someone had actually taken but what they believed they had taken. A 2024 review of the controlled evidence reached the same broad conclusion: once you account for expectancy, the specific benefit of microdosing is, at best, hard to find.4 That does not prove microdosing does nothing for everyone, but it does mean the strong personal stories are very likely driven, in large part, by the powerful and genuine effect of hope and expectation, which is worth respecting in its own right but is not the same as a drug effect.

Complex trauma and PTSD: the evidence is earlier still, and the cautions are larger

For trauma specifically, the evidence base is much thinner than for depression. Research into psilocybin for post-traumatic stress disorder is at a very early stage, mostly preclinical work and small early trials, with controlled studies only now under way.5 The psychedelic that had accumulated the most trauma evidence was actually a different drug, MDMA, in MDMA-assisted therapy. And tellingly, despite two positive late-stage trials, the US regulator (the FDA) declined to approve it in 2024, asking for more data and raising concerns about trial design and safety.5 That is a sobering reminder of how far "promising early results" can be from "established treatment."

There is also a specific clinical caution for complex trauma. A full psychedelic experience can bring buried material vividly to the surface. In a trial, that happens with a trained therapist present and a plan for integrating it afterwards. Alone, or unprepared, the same surfacing can be overwhelming and destabilising, and there is a real risk of re-traumatisation rather than relief. For people with a trauma history, this is precisely the situation in which doing it unsupported is most likely to do harm.

Why the setting matters more than the molecule

If there is one idea to take from the research, it is this: in the trials, the drug is only part of the intervention. The preparation, the safe and held environment, the trained people in the room, and the structured work of making sense of the experience afterwards are doing a great deal of the work. Researchers talk about "set and setting," meaning the person's mindset and the environment, because these shape the outcome enormously. This is the core reason that the supervised-trial results cannot simply be transplanted to someone taking mushrooms at home, and why the gap between the two is not a technicality but the whole point.

The UK legal reality, and the legal options that do exist

In the UK, psilocybin is a Class A drug and sits in Schedule 1, the most tightly controlled category, alongside the most restricted substances.6 In plain terms, it is illegal to possess, produce or supply, and outside of a licensed research setting there is no lawful way to access it. There has been genuine policy movement, a 2023 parliamentary committee called for rescheduling to make research easier, and the issue is under official review, but as things stand the law has not changed.6

Within the law, there are still some routes worth knowing about:

• Clinical trials. This is the only lawful way to receive psilocybin therapy in the UK, and it comes with exactly the screening and support that make it safer. UK research centres such as

Imperial College London's Centre for Psychedelic Research

run studies, and trials are listed on public registries such as the ISRCTN registry and ClinicalTrials.gov. Eligibility is strict, and there are never any guarantees of a place.

• Ketamine. Quite separately, ketamine is a legal medicine (it sits in a less restricted schedule), and ketamine-assisted approaches for severe depression are offered in some UK clinics, usually privately. It is worth noting that a specific licensed form, esketamine, was not recommended by NICE for routine NHS use in treatment-resistant depression, so access is limited and the evidence is still debated. This is not psilocybin, but it is the nearest thing to a legally available option in this space, and any decision about it belongs with a medical specialist.
• Treatment abroad. Psilocybin-style retreats operate legally in a few countries. I mention this only for completeness and with real caution: such settings vary enormously, are typically outside any medical or regulatory framework, can be expensive, and carry their own safety, screening and legal risks. It is not something I can endorse or guide.

The real risks, stated plainly

• Mental-health risk. A personal or family history of psychosis or bipolar disorder is a serious red flag, as psychedelics can trigger or worsen these. Trials screen people out for exactly this reason.
• Challenging experiences. Full doses can produce intense fear, confusion and distress, and for someone with trauma this can be destabilising rather than healing without proper support.
• Dangerous interactions. Psychedelics can interact with common medications. The combination with lithium, in particular, has been linked to seizures and serious harm, and antidepressants can interact too. This is one of many reasons it is never a do-it-yourself matter.
• Physical and other risks. Effects on heart rate and blood pressure, rare but lasting perceptual changes, and, with wild or unregulated mushrooms, the very real danger of misidentifying a poisonous species.
• Legal risk. Possession of a Class A drug carries serious legal consequences.

Where I land

Holding it all together: the science on supervised, high-dose psilocybin therapy for treatment-resistant depression is genuinely promising and worth watching, the evidence for microdosing is weak once you control for expectation, the evidence for trauma is earlier and the cautions larger, and none of it is legal or available as a treatment in the UK today. The powerful anecdotes are real experiences, and I do not dismiss them, but they are not the same as proof, and the conditions that make the clinical results possible are precisely the ones that are missing when someone tries this alone.

So my honest position, as a psychologist and not a doctor, is that this is a field to follow with interest and an open mind, not a treatment to pursue off the back of an article. If you are living with depression that has not responded, or with trauma, there are established, legal, evidence-based routes that deserve to be tried and properly supported first: trauma-focused therapies such as

EMDR

and trauma-focused CBT, the talking therapies and medications your GP and the NHS can offer, and, where depression is severe and resistant, a referral to specialist mental-health services who can discuss the full range of options with you safely.

This article is general information and a summary of published research. It is not medical, legal or clinical advice, it cannot replace an assessment by a doctor or specialist, and nothing in it should be read as encouragement to obtain or use an illegal substance. If you are in distress, you can talk to the

Samaritans

on 116 123 (free, any time), contact NHS 111, or, in an emergency, call 999. If you would like support of your own, the

free 10-minute consultation

is one place to start.

References and further reading

• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022;387(18):1637–1648.

doi:10.1056/NEJMoa2206443

• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021;384(15):1402–1411.

doi:10.1056/NEJMoa2032994

• Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878.

doi:10.7554/eLife.62878

• Polito V, Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. Journal of Psychopharmacology. 2024.

doi:10.1177/02698811241254831

• US National Center for PTSD. Psychedelic-assisted therapy for PTSD: an overview of the evidence (and the 2024 FDA decision on MDMA-assisted therapy).

ptsd.va.gov

• UK Parliament POST. Psychedelic-assisted therapy for mental health: policy considerations; and Talk to FRANK, Magic mushrooms (UK legal status and risks).

post.parliament.uk ·

talktofrank.com

This summary is current to mid-2026, in a fast-moving area where both the evidence and the law may change. It reflects published research and UK guidance and is offered for information only, by a counselling psychologist who is not a medical doctor and is not recommending any treatment.